Aptamerlab

Executive Summary

Aptamerlab is a European biotechnology company headquartered in Copenhagen, founded in 2015, that specializes in the development and application of aptamers – synthetic oligonucleotides with high specificity for target molecules. The company offers a full-service platform encompassing aptamer selection, characterization, 3D structure simulation, and target identification, primarily serving the diagnostics and therapeutic discovery sectors. Aptamerlab's technology is validated on real clinical samples, ensuring high sensitivity and specificity. By providing a robust alternative to antibodies, the company is poised to address unmet needs in biomarker discovery, point-of-care diagnostics, and targeted therapy. Despite operating in a competitive landscape, Aptamerlab's focus on custom aptamer services and its European base position it as a niche player with potential for growth as the aptamer market expands. The company is privately held and has not disclosed funding or valuation details, suggesting an early or growth-stage profile with limited public visibility. With the global aptamer market projected to grow significantly, Aptamerlab is well-placed to capitalize on increasing demand for high-specificity molecular recognition tools in research and clinical applications.

Upcoming Catalysts (preview)

• TBDSeries B Funding Announcement65% success
• TBDLaunch of First Commercial Diagnostic Test50% success
• TBDStrategic Partnership with Pharma/Biotech60% success